© 2020 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Hematology | Clinical
Novel Assay Identifies Mutations, Fusions, Exon Skipping in Myeloid and Lymphoid Malignancies
November 20, 2020
In an interview with Targeted Oncology during the Association for Molecular Pathology 2020 Annual Meeting, Rachel Sparks, MD, discussed the findings observed in hematologic malignancies with the use of a new RNA-based NGS assay.
FDA Grants Fast Track Designation to Rilzabrutinib for Treatment of Immune Thrombocytopenia
November 18, 2020
The FDA has granted a Fast Track designation to rilzabrutinib, an oral investigational Bruton’s tyrosine kinase inhibitor, for the treatment of immune thrombocytopenia. The drug was previously granted Orphan Drug designation for this indication.
Sequencing TP53 Mutations in Myeloid Neoplasms
November 17, 2020
Routine testing for the presence of TP53 mutations in myeloid neoplasms by sequencing will become an important part of routine care as TP53-targeting agents become available, according to a poster presented at the Association for Molecular Pathology 2020 Annual Meeting and Expo.
The Possibilities in AML With the FDA Approval of Azacitidine and Venetoclax
November 16, 2020
Brain A. Jonas, MD, discusses the future of treatment for older patients with acute myeloid leukemia, now that the FDA has granted approval to azacitidine plus venetoclax for patients aged 75 years or older.
CAR T Cell Therapy Shows Efficacy in B Cell Malignancies in Phase 1 Trial
November 15, 2020
Nirav N. Shah, MD, discusses bispecific anti-CD20 and anti-CD19 chimeric antigen receptor T cells in a phase 1 dose escalation and expansion trial for relapsed B cell malignancies.
Azacitidine/Venetoclax Represents New Gold Standard for Older Patients with Treatment-Naïve AML
November 13, 2020
In an interview with Targeted Oncology following the announcement of the FDA approval of azacitidine plus venetoclax in older patients with acute myeloid leukemia, Brian Jonas, MD, provided insight on the VILAE-A study results. He also gave expert advice on how to approach treating older patients with acute myeloid leukemia in every day practice.
The Ongoing Fight Against Acute GvHD
November 06, 2020
A key opinion leader provides insight into recent data updates from ongoing trials studying the management of GvHD with promising regimens.
Outcomes in Lower-Risk MDS Advance As Novel Strategies Emerge
November 04, 2020
Outcomes for patients with myelodysplastic syndrome range from a median of 5.3 years in the lower-risk population to 8.4 months among patient with very high-risk disease. These outcomes are changing as novel therapies for the lower-risk population enter the treatment landscape.
What Is the Role of Allogeneic-SCT in Adult Acute Lymphoblastic Leukemia in the Era of Targeted Therapies?
October 21, 2020
There are several indications for the use of allo-SCT in adults. With the implementation of targeted therapies, these are continuously changing.
FDA-Approved Oral Hypomethylating Agent Regimen Excites MDS Landscape
October 20, 2020
Guillermo Garcia-Manero, MD, discusses how the recently approved combination regimen of decitabine and cedazuridine fits into the treatment landscape for patients with myelodysplastic syndromes.